已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study

医学 安慰剂 队列 内科学 不利影响 剂量范围研究 2型糖尿病 恶心 胰高血糖素样肽1受体 肥胖 置信区间 胰高血糖素样肽-1 队列研究 糖尿病 兴奋剂 胃肠病学 内分泌学 受体 病理 双盲 替代医学
作者
Neeta B. Amin,Robert Frederich,Nikolaos Tsamandouras,Amina Z. Haggag,Tilman Schuster,Witold Żmuda,Alexandra Palmer,Szilárd Vasas,Gina Buckley,Timothy R. Smith,Sarah Dubrava,Qi Zhu,Margot Johnson
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
被引量:6
标识
DOI:10.1111/dom.16005
摘要

Abstract Aim The aim was to investigate the effects of lotiglipron, a once‐daily, oral small‐molecule glucagon‐like peptide‐1 (GLP‐1) receptor agonist, in participants with type 2 diabetes (T2D) or obesity. Materials and Methods A phase 2, randomized, double‐blind, placebo‐controlled, dose‐ranging study investigated the efficacy and safety of lotiglipron. The study was terminated early for safety reasons after routine data and monitoring review. The planned analyses for the end points were modified prior to unblinding the study. Results In total, 901 participants were treated with at least one dose of the study drug (T2D cohort: n = 512, obesity cohort: n = 389). Although the majority of participants who were randomly assigned to higher doses did not reach their target maintenance dose, statistically significant changes in HbA1c and body weight were observed. In the T2D cohort, reductions in HbA1c were observed across all lotiglipron doses at week 16 ( p < 0.0001), with least squares mean decreases up to −1.44% (90% confidence interval [CI]: −1.63, −1.26) (lotiglipron 80 mg), versus placebo, −0.07% (90% CI: −0.25, 0.11). In the obesity cohort, decreases in body weight were observed across all lotiglipron doses at week 20 ( p < 0.01), up to −7.47% (90% CI: −8.50, −6.43) (lotiglipron 200 mg, five‐step titration), versus placebo, −1.84% (90% CI: −2.85, −0.83). Across cohorts, the most frequently reported treatment‐emergent adverse events were gastrointestinal related (most mild to moderate severity), with nausea being the most common (ranging from 4% [placebo] to 28.8% [80 mg] in the T2D cohort and 12.5% [placebo] to 60.6% [200 mg, four‐step titration] in the obesity cohort). Transaminase elevations were observed in a subset of participants (6.6% and 6.0% of participants on lotiglipron in the T2D and obesity cohorts, respectively, compared with 1.6% on placebo in the obesity cohort). Conclusions The efficacy (HbA1c and/or body weight) of a range of lotiglipron doses was demonstrated in T2D and obesity cohorts. The safety profile was largely consistent with what has been previously known about the mechanism of action. Our results are unique in reporting elevations in liver transaminases in a subset of participants treated with lotiglipron, with attempts to identify the at‐risk population unsuccessful and therefore clinical development of lotiglipron terminated. ClinicalTrials.gov NCT05579977.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
迷路的百褶裙完成签到,获得积分10
2秒前
Crw__发布了新的文献求助10
4秒前
13508104971发布了新的文献求助10
7秒前
0000完成签到 ,获得积分10
9秒前
博修发布了新的文献求助100
10秒前
wzytu3完成签到,获得积分10
13秒前
在水一方应助科研通管家采纳,获得10
15秒前
科研通AI2S应助科研通管家采纳,获得10
15秒前
爆米花应助科研通管家采纳,获得10
15秒前
bkagyin应助科研通管家采纳,获得10
15秒前
柯一一应助科研通管家采纳,获得10
15秒前
小稻草人应助科研通管家采纳,获得10
15秒前
15秒前
15秒前
15秒前
w5566完成签到 ,获得积分10
16秒前
斯文招牌完成签到,获得积分10
17秒前
林攸之完成签到,获得积分10
18秒前
orixero应助wzytu3采纳,获得10
19秒前
a553355发布了新的文献求助10
20秒前
坐宝马吃地瓜完成签到 ,获得积分10
24秒前
量子星尘发布了新的文献求助10
28秒前
善学以致用应助博修采纳,获得10
31秒前
桐桐应助LNN采纳,获得10
33秒前
34秒前
公西傲蕾发布了新的文献求助20
34秒前
677发布了新的文献求助10
38秒前
38秒前
38秒前
40秒前
陈住气发布了新的文献求助10
41秒前
43秒前
LNN发布了新的文献求助10
44秒前
泥嚎关注了科研通微信公众号
45秒前
可靠草丛发布了新的文献求助10
45秒前
JJ发布了新的文献求助10
45秒前
46秒前
阿亞完成签到,获得积分10
46秒前
没有伞的青春完成签到 ,获得积分10
50秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Cognitive Neuroscience: The Biology of the Mind (Sixth Edition) 1000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3959928
求助须知:如何正确求助?哪些是违规求助? 3506172
关于积分的说明 11128138
捐赠科研通 3238123
什么是DOI,文献DOI怎么找? 1789535
邀请新用户注册赠送积分活动 871803
科研通“疑难数据库(出版商)”最低求助积分说明 803024